Impact of GLP-1 receptor agonists on psoriasis and cardiovascular comorbidities: a narrative review
It all depends on your individual biology, but in my experience, combining them with other therapies can produce superior outcomes
Additional mechanisms are being developed such as PYY, GIP, amylin as a potential second activity to be combined with GLP-1RAs
Patients with a history of cholecystectomy (gallbladder removal) face no additional gallstone risk from GLP-1 therapy, as they have no gallbladder to form stones
Whether this unique pattern worsens the obese state or constitutes a favorable adaptation remains unclear, and the physiological and pathophysiological implications of the altered GH/IGF-I axis in obesity remain uncertain with GH neither being the cause nor the solution to reverse obesity
As obesity is linked with a multitude of health issues, including type 2 diabetes, cardiovascular diseases, and hormonal imbalances, the search for effective weight loss solutions has been relentless
